These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 32035693

  • 1. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
    Kumar S, Joga S, Biswas B, Dabkara D, Prasad KT, Singh N, Malik PS, Khurana S, Ganguly S, Muthu V, Batra U.
    Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
    [Abstract] [Full Text] [Related]

  • 2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y.
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [Abstract] [Full Text] [Related]

  • 3. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
    Byeon S, Cho JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
    [Abstract] [Full Text] [Related]

  • 4. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I, GFPC Team.
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [Abstract] [Full Text] [Related]

  • 5. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, Hisakane K, Takahashi S, Tanaka T, Takeuchi S, Miyanaga A, Minegishi Y, Noro R, Kubota K, Gemma A.
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
    Luciani A, Marra A, Toschi L, Cortinovis D, Fava S, Filipazzi V, Tuzi A, Cerea G, Rossi S, Perfetti V, Rossi A, Giannetta L, Sala L, Finocchiaro G, Pizzutilo EG, Carelli S, Agustoni F, Cergnul M, Zonato S, Siena S, Bidoli P, Ferrari D.
    Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
    [Abstract] [Full Text] [Related]

  • 7. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM, Aerts J, van den Heuvel M, Hiltermann TJN, Bahce I, Smit EF, Dingemans AC, Hendriks LE, Stigt JA, Schramel FMNH, van Tinteren H, Groen HJM, all participants of NVALT Immunotherapy Register (see addendum).
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [Abstract] [Full Text] [Related]

  • 8. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
    Zhang L, Bai L, Liu X, Liu Y, Li S, Liu J, Zhang S, Yang C, Ren X, Cheng Y.
    Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
    [Abstract] [Full Text] [Related]

  • 9. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S, Komiya T, Powell E.
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [Abstract] [Full Text] [Related]

  • 10. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.
    Karayama M, Yoshizawa N, Sugiyama M, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Goshima S, Suda T, Takehara Y.
    Lung Cancer; 2020 May; 143():47-54. PubMed ID: 32203770
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H, Azuma K, Kawahara A, Kinoshita T, Matsuo N, Naito Y, Tokito T, Yamada K, Akiba J, Hoshino T.
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S, Choi YD, Kim J, Kho BG, Park CK, Oh IJ, Kim YC.
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
    Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G.
    Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM, Tu HY, Yang JJ, Zhang XC, Zhou Q, Xu CR, Jiang BY, Yang XN, Yang XR, Deng JY, Yang MY, Xu BF, Chen XM, Li YS, Wu YL.
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [Abstract] [Full Text] [Related]

  • 15. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M.
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [Abstract] [Full Text] [Related]

  • 16. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N, Jones G, Beeler JF, Plagnol V, Morris C, Mourlanette J, Delaunay M, Keller L, Rouquette I, Favre G, Pradines A, Mazieres J.
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A, Foca F, Menis J, Stucci SL, Artioli F, Guadalupi V, Forcignanò MR, Fantini M, Recine F, Mercatali L, Spadazzi C, Burgio MA, Fausti V, Miserocchi A, Ibrahim T.
    Front Immunol; 2021 Nov; 12():697298. PubMed ID: 34858389
    [Abstract] [Full Text] [Related]

  • 19. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [Abstract] [Full Text] [Related]

  • 20. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM.
    Clin Lung Cancer; 2021 Jan; 22(1):e57-e62. PubMed ID: 32900613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.